0

Close
 
Upcoming Allied Market Research
2023
Liquid-based, Needle-free Injector Market

Liquid-based, Needle-Free Injector Market

by Type (Jet, Spring, Laser, Vibration) and by End User (Hospitals, Clinics): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Medical Devices & Supplies
Report Code: A02411
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Liquid-based, Needle-free Injector Market

Request Now !

Needle-free injection is a technology enables the delivery of drug through the skin, virtually nullifying the use of hypodermic needle. Liquid-based, needle-free injectors are used when the drug loaded in the injection is in the liquid form. This technology is highly beneficial for the evolving pharma industry. It is useful in mass immunization programmers, since it reduces the chances of needlestick injuries and other complications, including those arising due to multiple use of a single needle.

No complications with multiple use of single needle, low chances of developing needlestick injuries, and advancement in the technology for the development of liquid-based, needle-free injectors drive the growth of the global liquid-based, needle-free injectors market. However, certain technology-based challenges restrain the growth of the market.

The report segments the liquid-based, needle-free injector market on the basis of type, end user, and geography. Based on type, the market is categorized into jet, spring, laser, and vibration. By end user, it bifurcated into hospitals and clinic. Geographical breakdown and deep analysis of each of the aforesaid segments is included for North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Antares Pharma, Inc. and other companies operating in the Global Liquid-Based Needle-Free Injectors Market would be covered in the report.

Key Benefits

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global liquid based needle free injectors market.
  • In-depth analysis has been done in this report by constructing market estimations for the key market segments.
  • This report entails the detailed quantitative analysis of the current trends and future estimations which assists to identify the prevailing market opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • Exhaustive analysis of the global market by type helps to understand the types of liquid-based, needle-free injectors that are currently being used along with the variants that are expected to gain prominence in the future.
  • An in-depth analysis of current research and clinical developments within the market is provided with key factors that help to understand the behavior of the market

 Liquid-based, Needle-Free Injector Market Report Highlights

Aspects Details
By Type
  • Jet
  • Spring
  • Laser
  • Vibration
By End User
  • Hospitals
  • Clinics
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Endo International, National Medical Products, Antares Pharma, Bioject Medical Technologies, Crossject SA, Valeritas, European Pharma Group, Medical International Technology
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Jet

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Spring

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Laser

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Vibration

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Clinics

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Liquid-based, Needle-free Injector Market

        • 6.2.5.1. Market Size and Forecast, By Type
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Liquid-based, Needle-free Injector Market

        • 6.2.6.1. Market Size and Forecast, By Type
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Liquid-based, Needle-free Injector Market

        • 6.2.7.1. Market Size and Forecast, By Type
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Liquid-based, Needle-free Injector Market

        • 6.3.5.1. Market Size and Forecast, By Type
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Liquid-based, Needle-free Injector Market

        • 6.3.6.1. Market Size and Forecast, By Type
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Liquid-based, Needle-free Injector Market

        • 6.3.7.1. Market Size and Forecast, By Type
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Liquid-based, Needle-free Injector Market

        • 6.3.8.1. Market Size and Forecast, By Type
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Liquid-based, Needle-free Injector Market

        • 6.3.9.1. Market Size and Forecast, By Type
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Liquid-based, Needle-free Injector Market

        • 6.3.10.1. Market Size and Forecast, By Type
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Liquid-based, Needle-free Injector Market

        • 6.3.11.1. Market Size and Forecast, By Type
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Liquid-based, Needle-free Injector Market

        • 6.4.5.1. Market Size and Forecast, By Type
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Liquid-based, Needle-free Injector Market

        • 6.4.6.1. Market Size and Forecast, By Type
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Liquid-based, Needle-free Injector Market

        • 6.4.7.1. Market Size and Forecast, By Type
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Liquid-based, Needle-free Injector Market

        • 6.4.8.1. Market Size and Forecast, By Type
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Liquid-based, Needle-free Injector Market

        • 6.4.9.1. Market Size and Forecast, By Type
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Liquid-based, Needle-free Injector Market

        • 6.4.10.1. Market Size and Forecast, By Type
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Liquid-based, Needle-free Injector Market

        • 6.4.11.1. Market Size and Forecast, By Type
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Liquid-based, Needle-free Injector Market

        • 6.4.12.1. Market Size and Forecast, By Type
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Liquid-based, Needle-free Injector Market

        • 6.4.13.1. Market Size and Forecast, By Type
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Liquid-based, Needle-free Injector Market

        • 6.5.5.1. Market Size and Forecast, By Type
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Liquid-based, Needle-free Injector Market

        • 6.5.6.1. Market Size and Forecast, By Type
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Liquid-based, Needle-free Injector Market

        • 6.5.7.1. Market Size and Forecast, By Type
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Liquid-based, Needle-free Injector Market

        • 6.5.8.1. Market Size and Forecast, By Type
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Liquid-based, Needle-free Injector Market

        • 6.5.9.1. Market Size and Forecast, By Type
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Liquid-based, Needle-free Injector Market

        • 6.5.10.1. Market Size and Forecast, By Type
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Antares Pharma

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Bioject Medical Technologies

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Medical International Technology

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Endo International

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. National Medical Products

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Valeritas

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. European Pharma Group

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Crossject SA

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR JET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR SPRING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR LASER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR VIBRATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 13. U.S. LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 14. U.S. LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 15. CANADA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 16. CANADA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 17. MEXICO LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 22. FRANCE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 23. FRANCE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 25. GERMANY LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. ITALY LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 27. ITALY LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. SPAIN LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 29. SPAIN LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. UK LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 31. UK LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. RUSSIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 33. RUSSIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 35. REST OF EUROPE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC LIQUID-BASED, NEEDLE-FREE INJECTOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. CHINA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 40. CHINA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. JAPAN LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 42. JAPAN LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. INDIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 44. INDIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. SOUTH KOREA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 47. AUSTRALIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 48. AUSTRALIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. THAILAND LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 50. THAILAND LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. MALAYSIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 52. MALAYSIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. INDONESIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 54. INDONESIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. LAMEA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 58. LAMEA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 60. BRAZIL LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 61. BRAZIL LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. SOUTH AFRICA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 63. SOUTH AFRICA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. SAUDI ARABIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 65. SAUDI ARABIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 66. UAE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 67. UAE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. ARGENTINA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 69. ARGENTINA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. REST OF LAMEA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 71. REST OF LAMEA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. ANTARES PHARMA: KEY EXECUTIVES
  • TABLE 73. ANTARES PHARMA: COMPANY SNAPSHOT
  • TABLE 74. ANTARES PHARMA: OPERATING SEGMENTS
  • TABLE 75. ANTARES PHARMA: PRODUCT PORTFOLIO
  • TABLE 76. ANTARES PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 77. BIOJECT MEDICAL TECHNOLOGIES: KEY EXECUTIVES
  • TABLE 78. BIOJECT MEDICAL TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 79. BIOJECT MEDICAL TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 80. BIOJECT MEDICAL TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 81. BIOJECT MEDICAL TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. MEDICAL INTERNATIONAL TECHNOLOGY: KEY EXECUTIVES
  • TABLE 83. MEDICAL INTERNATIONAL TECHNOLOGY: COMPANY SNAPSHOT
  • TABLE 84. MEDICAL INTERNATIONAL TECHNOLOGY: OPERATING SEGMENTS
  • TABLE 85. MEDICAL INTERNATIONAL TECHNOLOGY: PRODUCT PORTFOLIO
  • TABLE 86. MEDICAL INTERNATIONAL TECHNOLOGY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. ENDO INTERNATIONAL: KEY EXECUTIVES
  • TABLE 88. ENDO INTERNATIONAL: COMPANY SNAPSHOT
  • TABLE 89. ENDO INTERNATIONAL: OPERATING SEGMENTS
  • TABLE 90. ENDO INTERNATIONAL: PRODUCT PORTFOLIO
  • TABLE 91. ENDO INTERNATIONAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. NATIONAL MEDICAL PRODUCTS: KEY EXECUTIVES
  • TABLE 93. NATIONAL MEDICAL PRODUCTS: COMPANY SNAPSHOT
  • TABLE 94. NATIONAL MEDICAL PRODUCTS: OPERATING SEGMENTS
  • TABLE 95. NATIONAL MEDICAL PRODUCTS: PRODUCT PORTFOLIO
  • TABLE 96. NATIONAL MEDICAL PRODUCTS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. VALERITAS: KEY EXECUTIVES
  • TABLE 98. VALERITAS: COMPANY SNAPSHOT
  • TABLE 99. VALERITAS: OPERATING SEGMENTS
  • TABLE 100. VALERITAS: PRODUCT PORTFOLIO
  • TABLE 101. VALERITAS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. EUROPEAN PHARMA GROUP: KEY EXECUTIVES
  • TABLE 103. EUROPEAN PHARMA GROUP: COMPANY SNAPSHOT
  • TABLE 104. EUROPEAN PHARMA GROUP: OPERATING SEGMENTS
  • TABLE 105. EUROPEAN PHARMA GROUP: PRODUCT PORTFOLIO
  • TABLE 106. EUROPEAN PHARMA GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. CROSSJECT SA: KEY EXECUTIVES
  • TABLE 108. CROSSJECT SA: COMPANY SNAPSHOT
  • TABLE 109. CROSSJECT SA: OPERATING SEGMENTS
  • TABLE 110. CROSSJECT SA: PRODUCT PORTFOLIO
  • TABLE 111. CROSSJECT SA: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET SEGMENTATION
  • FIGURE 2. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET
  • FIGURE 3. SEGMENTATION LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALLIQUID-BASED, NEEDLE-FREE INJECTOR MARKET
  • FIGURE 11. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR JET, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR SPRING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR LASER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR VIBRATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET SEGMENTATION, BY BY END USER
  • FIGURE 17. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 20. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 21. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 22. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 23. COMPETITIVE DASHBOARD
  • FIGURE 24. COMPETITIVE HEATMAP: LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET
  • FIGURE 25. Top player positioning, 2022
  • FIGURE 26. ANTARES PHARMA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 27. ANTARES PHARMA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 28. ANTARES PHARMA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 29. BIOJECT MEDICAL TECHNOLOGIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 30. BIOJECT MEDICAL TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 31. BIOJECT MEDICAL TECHNOLOGIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 32. MEDICAL INTERNATIONAL TECHNOLOGY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. MEDICAL INTERNATIONAL TECHNOLOGY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. MEDICAL INTERNATIONAL TECHNOLOGY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. ENDO INTERNATIONAL: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. ENDO INTERNATIONAL: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. ENDO INTERNATIONAL: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. NATIONAL MEDICAL PRODUCTS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. NATIONAL MEDICAL PRODUCTS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. NATIONAL MEDICAL PRODUCTS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. VALERITAS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. VALERITAS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. VALERITAS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. EUROPEAN PHARMA GROUP: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. EUROPEAN PHARMA GROUP: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. EUROPEAN PHARMA GROUP: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. CROSSJECT SA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. CROSSJECT SA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. CROSSJECT SA: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Liquid-based, Needle-free Injector Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers